AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 JUL 10 - (NewsRx.com & NewsRx.net) -- by Maria G. Essig, MS, ELS, senior medical writer - Tumor cells expressing granulocyte macrophage-colony stimulating factor (GM-CSF) showed feasibility as an adjuvant for vaccines against GM-CSF-producing tumors, according to a recent report.
"The injection of irradiated tumor cells genetically engineered to express the granulocyte macrophage-colony stimulating factor (GM-CSF) is reported as stimulating antitumoral immunity in several animal models," explained F. Lefranc and colleagues at Erasme Academic Hospital in Brussels. "We used the 9L gliosarcoma rat model to investigate the potency of this strategy in relation to the central nervous system."
The investigators produced 9L murine cells expressing GM-CSF (9LmGM-CSF) by in vitro transduction. Rats that received 10[superscript]6 to 10[superscript]8 9LmGM-CSF cells subcutaneously did not develop 9L gliosarcomas (with one exception). However, rats given naive 9L cells subcutaneously die 25 to 45 days after inoculation (Granulocyte macrophage-colony stimulating factor gene transfer to induce a protective anti-tumoral immune response against the 9L rat gliosarcoma model, International Journal of Oncology, ...